3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
33
Pancreatic Neoplasms
14
Neuroblastoma
12
Neoplasm Metastasis
10
Stomach Neoplasms
8
Neoplasms
8
Rectal Neoplasms
5
Small Cell Lung Carcinoma
4
Esophageal Squamous Cell Carcinoma
4
Colonic Neoplasms
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Ovarian Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Wilms Tumor
2
Sarcoma
2
Recurrence
2
Osteosarcoma
2
Gastrointestinal Neoplasms
2
Ganglioneuroblastoma
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Triple Negative Breast Neoplasms
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Solid Tumors
1
Interventions
Magnetic Resonance Spectroscopy
51
Specimen Handling
42
enzalutamide
35
Androgen Antagonists
34
Radiosurgery
32
Radiotherapy
31
Prednisone
26
darolutamide
24
Abiraterone Acetate
24
Leuprolide
22
Docetaxel
22
apalutamide
20
Pluvicto
19
abiraterone
18
Standard of Care
18
Triptorelin Pamoate
17
Radiation
17
Biopsy
16
relugolix
15
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Goserelin
14
Blood Specimen Collection
13
gallium 68 PSMA-11
12
pembrolizumab
11
X-Rays
11
Surveys and Questionnaires
11
luprolide acetate gel depot
10
Carboplatin
10
Methods
9
Interviews as Topic
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms
×
Irinotecan
×
Clear all
NCT06769425
2025-06-24
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
Recruiting
157 enrolled